Back to News
Market Impact: 0.25
Scarlet Therapeutics Secures DARPA Agreement to Develop Adaptive Smart Red Blood Cells
Source: GlobeNewswire
Healthcare & BiotechTechnology & Innovation
The company announced an agreement worth up to $14 million related to its red blood cell technology platform. The deal provides external validation of the platform’s commercial potential, although the article provides no details on upfront payments, milestones, counterparty, or expected financial timing.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
More News
- China's AI chip blitz arms Xi with a message for Trump: 'You can't choke us off'
- OpenAI’s agent hacked Australia’s Medicare website—the latest rogue AI incident that the company didn’t know about for months
- Meta announces new lightweight virtual reality glasses to one-up Apple’s Vision Pro
- US aviation sanctions disrupt Iran flights, push travellers overland
- Chinese authorities reportedly in possession of F-35 components in Hong Kong
- Australia says OpenAI agent hacked Medicare portal